Although immune checkpoint inhibitors (ICIs) have revolutionized the gastrointestinal cancer treatment landscape, offering durable clinical benefits in a subset of patients, their efficacy remains limited to this subset of patients, underscoring the urgent nee... ...

请注册登录后继续浏览